Friday, July 10, 2026
🇺🇸 FDA

Intelligence · Clinical pipeline

Metabolic & obesity R&D Pipeline

GLP-1, metabolic disease, obesity, and diabetes pipeline programs with sponsor and trial ID cross-links.

Programs 744

Quick answer

Metabolic & obesity: NovaPharmaNews indexes 744 metabolic & obesity clinical pipeline programs from ClinicalTrials.gov with phase, modality, NCT identifiers, and sponsor company links. GLP-1, metabolic disease, obesity, and diabetes pipeline programs with sponsor and trial ID cross-links.

Top sponsors

Pipeline programs

Page 12 of 16

  1. NN1436-7615

    NovoThirteen

    Type 2 diabetes

    phase 1 other active

    1 trial

  2. NN1471-5026

    NovoThirteen

    Diabetes mellitus type 2

    phase 1 other active

    1 trial

  3. NN1471-7712

    NovoThirteen

    Diabetes mellitus type 1

    phase 1 other active

    1 trial

  4. NN1644-7794

    NovoThirteen

    Type 1 diabetes mellitus

    phase 1 other active

    1 trial

  5. NN1644-8194

    NovoThirteen

    Diabetes type 1

    phase 1 other active

    1 trial

  6. NN1679-8505

    NovoThirteen

    Healthy participants and participants with type 2 diabetes

    phase 1 other active

    1 trial

  7. NN6022-7683

    NovoThirteen

    Cardiometabolic diseases

    phase 1 other active

    1 trial

  8. NN6497-8309

    NovoThirteen

    Type I diabetes

    phase 1 other active

    1 trial

  9. NN6497-8316

    NovoThirteen

    Diabetes mellitus type 1

    phase 1 other active

    1 trial

  10. NN6705-8141

    NovoThirteen

    Cardiometabolic diseases with an inflammatory component

    phase 1 other active

    1 trial

  11. NN9388-7782

    NovoThirteen

    Type 2 diabetes

    phase 1 other active

    1 trial

  12. NN9490-7611

    NovoThirteen

    Obesity and Diabetes mellitus Typ 2

    phase 1 other active

    1 trial

  13. NN9490-8151

    NovoThirteen

    Participants with obesity, but otherwise healthy

    phase 1 other active

    1 trial

  14. NN9490-8152

    NovoThirteen

    Obesity

    phase 1 other active

    1 trial

  15. NN9541-4922

    NovoThirteen

    Healthy postmenopausal females (Type 2 Diabetes)

    phase 1 other active

    1 trial

  16. NN9541-4923

    NovoThirteen

    Type 2 Diabetes Mellitus

    phase 1 other active

    1 trial

  17. NN9541-7760

    NovoThirteen

    Type 2 diabetes mellitus

    phase 1 other active

    1 trial

  18. NN9541-8116

    NovoThirteen

    Obesity, Type 2 Diabetes with either overweight or obesity

    phase 1 other active

    1 trial

  19. NN9733-8133

    NovoThirteen

    Healthy Participants and Participants with type 2 diabetes

    phase 1 other active

    1 trial

  20. NN9833-8285

    NovoThirteen

    obesity

    phase 1 other active

    1 trial

  21. NN9833-8421

    NovoThirteen

    Obesity

    phase 1 other active

    1 trial

  22. NN9838-4695

    NovoThirteen

    Obesity

    phase 1 other active

    1 trial

  23. NN9838-8411

    NovoThirteen

    Obesity, CCI, CCI

    phase 1 other active

    1 trial

  24. NNC0480-0389

    Novo Nordisk A/S

    Healthy Volunteers Type 2 Diabetes

    phase 1 small molecule completed

    1 trial

  25. Omega-3 fatty acids

    NORTHWEST BIOTHERAPEUTICS INC

    Metabolic Syndrome X

    phase 1 other active

    1 trial

  26. Oshadi Oral Insulin

    BRIGHT MINDS BIOSCIENCES INC.

    Diabetes

    phase 1 small molecule completed

    1 trial

  27. PF-05190457

    Pfizer

    Diabetes Mellitus, Type 2

    phase 1 small molecule completed

    1 trial

  28. Placebo

    Rhythm Pharmaceuticals Netherlands B.V.

    Obesity

    phase 1 small molecule completed

    1 trial

  29. ProHema-CB Transplant

    Zafatek

    Metabolic Disorders

    phase 1 mab terminated

    1 trial

  30. REGN1193

    Regeneron UK Limited

    Diabetes Mellitus, Type 2

    phase 1 small molecule terminated

    1 trial

  31. REGN1500

    Regeneron UK Limited

    Metabolic Disorders

    phase 1 small molecule completed

    1 trial

  32. REGN20934

    Regeneron UK Limited

    Overweight or Obesity

    phase 1 small molecule active

    1 trial

  33. RP-L301-0119

    Lacuna Pharma Pty Ltd

    Inherited metabolic disorder of the enzyme pyruvate kinase which affects the survival of red blood cells, Pyruvate Kinase Deficiency

    phase 1 small molecule active

    1 trial

  34. RT-114 is the RaniPill capsule with PG-102 for the treatment of obesity

    Rani Therapeutics Holdings

    Obesity

    phase 1 other active

    1 trial

  35. Rongliflozin

    Sunshine Guojian Pharmaceutical (Shanghai) Co.,

    Type 2 Diabetes Mellitus

    phase 1 small molecule completed

    1 trial

  36. Salvianolic Acid A

    The First People's Hospital of Lianyungang

    Neuropathy of Diabetes

    phase 1 small molecule active

    1 trial

  37. TAK-329

    Takeda

    Type 1 Diabetes Mellitus

    phase 1 small molecule completed

    1 trial

  38. TAK-648

    Takeda

    Type 2 Diabetes Mellitus

    phase 1 small molecule completed

    1 trial

  39. Tebipenem Pivoxil Hydrobromide

    Spero Therapeutics

    Diabetes

    phase 1 small molecule completed

    1 trial

  40. The Role of the Amylin Analogue Cagrilintide in Bone Metabolism

    NovoThirteen

    Female (aged between 50-70 years (both included)) with obesity (BMI ≥ 30.0 kg/m2) of post-menopausal state at screening (defined as minimum 12 months of amenorrhea and high levels of follicular stimulating hormone (FSH) ≥16 UI/L. In cases of uncertainty, confirmation of postmenopausal status requires low levels of anti-Müllerian hormone (AMH) and inhibin B).

    phase 1 other active

    1 trial

  41. UECHUP-DAP/24-4

    Laboratorios Tillomed Spain S.L.U

    Diabetes

    phase 1 other active

    1 trial

  42. UECHUP-LIN-MET/24-1

    Laboratorios Tillomed Spain S.L.U

    diabetes

    phase 1 other active

    1 trial

  43. UP421

    Sana Biotechnology

    Type1diabetes

    phase 1 mab active

    1 trial

  44. VCTX210A unit

    S.A.

    Diabetes Mellitus

    phase 1 other completed

    1 trial

  45. VCTX211

    S.A.

    Diabetes Mellitus

    phase 1 other terminated

    1 trial

  46. VEGF Trap-Eye

    Regeneron UK Limited

    Diabetic Macular Edema

    phase 1 small molecule completed

    1 trial

  47. XeriSol glucagon

    Xeris Biopharma Holdings

    Type1diabetes

    phase 1 small molecule completed

    1 trial

  48. [14C]-rencofilstat 225mg

    Hepion Pharmaceuticals

    NASH With Fibrosis

    phase 1 small molecule completed

    1 trial

Frequently asked questions

How many metabolic & obesity pipeline programs are tracked?

744 programs match this therapeutic area based on indication text, program name, and registry metadata.

Where does pipeline data come from?

ClinicalTrials.gov records linked to NovaPharmaNews company profiles. Verify on ClinicalTrials.gov before investment decisions.

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.